NCT06401538

BMB-101 in Epilepsy With Eyelid Myoclonia (EEM)

Name: Clinical Trial NCT06401538
Creator: Bright Minds Biosciences Pty Ltd
Keywords: Jeavons Syndrome, BMB-101, Phase 2, drug, clinical trial, Australia

An Open-Label Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of BMB-101 in Adolescents and Adults With Epilepsy With Eyelid Myoclonia (EEM; Jeavons Syndrome) Including Those With Prominent Photic Induction (Sunflower Syndrome)

Bright Minds Biosciences Pty Ltd·Phase 2·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Jeavons Syndrome
Drug/Device/Intervention: BMB-101
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Bright Minds Biosciences Pty Ltd
Location: Melbourne, Australia

Timeline & enrollment

Phase: Phase 2
Start date: Jul 15, 2024
End date: Oct 15, 2025
Enrollment: 20 participants

Primary outcome

Change from baseline in seizure frequency

Summary

The study is a pilot, open-label, study to test whether BMB-101 is safe and effective in reducing the frequency of seizures in subjects with Epilepsy with Eyelid Myoclonia (also called Jeavons Syndrome). The study will last up to 6 months. There will be a 1 month screening period, then 3 months on open-label BMB-101 including titration and tapering/washout periods, and then a 1 month follow-up period. There will be 7 clinic visits.

ICD-10 classifications

Melkersson syndromeGilbert syndromeCrigler-Najjar syndromeOther histiocytosis syndromesHELLP syndrome

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06401538
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06401538 through Pure Global AI's free database. This Phase 2 trial is sponsored by Bright Minds Biosciences Pty Ltd and is currently Not yet recruiting. The study focuses on Jeavons Syndrome. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.